Analysts expect Novavax, Inc. (NASDAQ:NVAX) to report $-0.14 EPS on May, 14.They anticipate $0.02 EPS change or 12.50% from last quarter’s $-0.16 EPS. After having $-0.16 EPS previously, Novavax, Inc.’s analysts see -12.50% EPS growth. The stock decreased 0.58% or $0.01 during the last trading session, reaching $1.71. About 3.83 million shares traded. Novavax, Inc. (NASDAQ:NVAX) has risen 53.85% since April 22, 2017 and is uptrending. It has outperformed by 42.30% the S&P500.
Among 12 analysts covering Torchmark Corporation (NYSE:TMK), 1 have Buy rating, 4 Sell and 7 Hold. Therefore 8% are positive. Torchmark Corporation had 37 analyst reports since July 29, 2015 according to SRatingsIntel. On Thursday, August 13 the stock rating was downgraded by Morgan Stanley to “Underweight”. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Wednesday, April 11 report. On Monday, August 3 the stock rating was upgraded by FBR Capital to “Market Perform”. Zacks upgraded the stock to “Sell” rating in Tuesday, August 25 report. Morgan Stanley maintained the shares of TMK in report on Thursday, April 5 with “Underweight” rating. The firm earned “Underperform” rating on Friday, November 18 by Bank of America. Credit Suisse initiated the shares of TMK in report on Friday, October 7 with “Neutral” rating. Keefe Bruyette & Woods maintained Torchmark Corporation (NYSE:TMK) on Thursday, December 21 with “Hold” rating. The company was maintained on Friday, November 10 by Keefe Bruyette & Woods. The rating was reinitiated by Wells Fargo with “Underperform” on Friday, September 23. See Torchmark Corporation (NYSE:TMK) latest ratings:
19/04/2018 Broker: SunTrust Rating: Hold New Target: $89.0000 Maintain
11/04/2018 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $93.0000 Maintain
05/04/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Underweight Old Target: $84 New Target: $82 Maintain
26/03/2018 Broker: Bank of America Rating: Buy New Target: $97.0000
02/03/2018 Broker: UBS Rating: Sell New Target: $83 Initiates Coverage On
08/01/2018 Broker: Barclays Capital Rating: Sell New Target: $82.0
21/12/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $96.0 Maintain
13/11/2017 Broker: Morgan Stanley Rating: Underweight Old Target: $76 New Target: $78 Maintain
10/11/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $83.0 Maintain
26/10/2017 Broker: SunTrust Rating: Hold Old Target: $75 New Target: $85 Maintain
Investors sentiment increased to 1 in 2017 Q4. Its up 0.18, from 0.82 in 2017Q3. It increased, as 27 investors sold Torchmark Corporation shares while 143 reduced holdings. 59 funds opened positions while 111 raised stakes. 79.58 million shares or 0.47% more from 79.21 million shares in 2017Q3 were reported. Ajo Limited Partnership has invested 0.04% of its portfolio in Torchmark Corporation (NYSE:TMK). 52,029 were reported by Retirement System Of Alabama. Moreover, Gofen And Glossberg Limited Liability Il has 0.01% invested in Torchmark Corporation (NYSE:TMK) for 2,391 shares. Srb Corp invested in 0.03% or 2,306 shares. M&R stated it has 0.54% of its portfolio in Torchmark Corporation (NYSE:TMK). Co Fincl Bank invested in 0% or 2,395 shares. Neuberger Berman Grp invested 0.02% in Torchmark Corporation (NYSE:TMK). Fjarde Ap has 0.05% invested in Torchmark Corporation (NYSE:TMK) for 34,740 shares. Financial Bank Of New York Mellon invested in 0.02% or 994,123 shares. Estabrook Management has 0.01% invested in Torchmark Corporation (NYSE:TMK) for 900 shares. Kansas-based Creative Planning has invested 0% in Torchmark Corporation (NYSE:TMK). Bluemountain Ltd Limited Liability Company invested 0.17% of its portfolio in Torchmark Corporation (NYSE:TMK). Thrivent Financial For Lutherans owns 4,373 shares or 0% of their US portfolio. 18,450 are held by Lingohr & Partner Asset Gmbh. Eulav Asset Management owns 23,900 shares for 0.1% of their portfolio.
Torchmark Corporation, through its subsidiaries, provides various life and health insurance products, and annuities in the United States, Canada, and New Zealand. The company has market cap of $9.93 billion. It operates through Life Insurance, Health Insurance, and Annuities divisions. It has a 7.13 P/E ratio. The Life Insurance segment offers life insurance products, including traditional and interest-sensitive whole life and term life insurance, and other life insurance.
Since October 26, 2017, it had 0 insider purchases, and 20 sales for $35.59 million activity. Shares for $1.92 million were sold by MAJORS MICHAEL CLAY on Monday, February 26. 11,000 shares were sold by DICHIARO STEVEN JOHN, worth $930,324. On Tuesday, March 27 the insider COLEMAN GARY L sold $420,406. The insider LUTEK BEN sold 52,500 shares worth $4.41 million. Darden James Matthew sold $1.16M worth of stock. Shares for $50,616 were sold by ZUCCONI PAUL J on Thursday, October 26. LEAVELL BILL sold 18,750 shares worth $1.58M.
The stock decreased 0.05% or $0.04 during the last trading session, reaching $87.18. About 792,054 shares traded or 13.28% up from the average. Torchmark Corporation (NYSE:TMK) has risen 8.95% since April 22, 2017 and is uptrending. It has underperformed by 2.60% the S&P500.
Since January 31, 2018, it had 1 buying transaction, and 0 insider sales for $11,250 activity. Glenn Gregory M bought $11,250 worth of Novavax, Inc. (NASDAQ:NVAX) on Wednesday, January 31.
Among 13 analysts covering Novavax (NASDAQ:NVAX), 6 have Buy rating, 2 Sell and 5 Hold. Therefore 46% are positive. Novavax had 35 analyst reports since August 11, 2015 according to SRatingsIntel. As per Monday, April 4, the company rating was initiated by Chardan Capital Markets. Citigroup upgraded the shares of NVAX in report on Tuesday, October 31 to “Buy” rating. As per Monday, March 19, the company rating was downgraded by JP Morgan. On Wednesday, August 9 the stock rating was upgraded by Ladenburg Thalmann to “Buy”. On Friday, September 16 the stock rating was maintained by FBR Capital with “Outperform”. The stock of Novavax, Inc. (NASDAQ:NVAX) earned “Neutral” rating by Citigroup on Tuesday, December 19. The rating was maintained by Piper Jaffray with “Hold” on Monday, July 24. The rating was upgraded by Citigroup to “Buy” on Thursday, March 1. As per Thursday, August 10, the company rating was maintained by Cantor Fitzgerald. J.P. Morgan downgraded Novavax, Inc. (NASDAQ:NVAX) on Monday, March 19 to “Sell” rating.
Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company has market cap of $651.75 million. The firm develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It currently has negative earnings. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.
Investors sentiment increased to 1.37 in 2017 Q4. Its up 0.11, from 1.26 in 2017Q3. It increased, as 13 investors sold Novavax, Inc. shares while 30 reduced holdings. 20 funds opened positions while 39 raised stakes. 124.34 million shares or 9.13% more from 113.94 million shares in 2017Q3 were reported. Ny State Common Retirement Fund has 293,448 shares. Hightower Advsrs Ltd Liability Corporation holds 0% of its portfolio in Novavax, Inc. (NASDAQ:NVAX) for 109,800 shares. Jacobs Levy Equity holds 1.59M shares or 0.03% of its portfolio. Alliancebernstein Limited Partnership owns 253,301 shares for 0% of their portfolio. Brown Advisory Incorporated has invested 0% in Novavax, Inc. (NASDAQ:NVAX). State Street accumulated 12.11M shares or 0% of the stock. Ameriprise Fincl owns 3.18M shares. Parallax Volatility Advisers L P has invested 0% in Novavax, Inc. (NASDAQ:NVAX). Architects accumulated 1,500 shares or 0% of the stock. Schwab Charles Management reported 0% in Novavax, Inc. (NASDAQ:NVAX). Weiss Asset Management Limited Partnership holds 0% of its portfolio in Novavax, Inc. (NASDAQ:NVAX) for 23,062 shares. Fifth Third Fincl Bank holds 0% of its portfolio in Novavax, Inc. (NASDAQ:NVAX) for 100 shares. Franklin Resources reported 3.43 million shares. Tradewinds Capital Mgmt Ltd Llc invested in 16,000 shares or 0.01% of the stock. Advisory Svcs Limited Liability reported 2,200 shares.